Revolution Medicines

cancer target detection radiopharma radio
Biotech

Revolution’s RAS inhibitor hits key goals in ph. 3 cancer trial

Daraxonrasib helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy.
James Waldron Apr 13, 2026 8:00am
Graphic of a line of blocks with percentages on them with one block in yellow showing an arrow increasing

Small molecules are 'resurgent' in orphan drug R&D: Evaluate

Mar 12, 2026 10:30am
Takeda

Takeda inks $1.7B AI discovery deal with Iambic Therapeutics

Feb 9, 2026 8:00am
accelerated

Regeneron, Sanofi receive 1- to 2-month priority review vouchers

Oct 17, 2025 8:30am
Parachute over a mountain in Switzerland

GSK chief steps down in stunning move—Chutes & Ladders

Oct 3, 2025 8:30am
Group of scientist or doctors and nurses wearing blue protective gloves putting their hands together

Revolution taps Iambic's AI models in $25M discovery deal

Jul 9, 2025 11:19am